Stay updated with the latest company events and announcements
| Event Date | Event Title | Event Summary | Event URL |
|---|---|---|---|
N/A | Rights Issue | INR 3500 Cr CCPS B rights issue at INR 96.8 | View Event |
N/A | Annual General Meeting | AGM of Pharmeasy in 2023 | View Event |
PharmEasy Unlisted Shares
PharmEasy is India’s leading digital healthcare platform. It provides information, consultations, diagnostics tests, medicines, healthcare products, and services from registered and trusted pharmacies, leading diagnostic laboratories, and trusted doctors across India, serving every habitable zip code of the country. The journey of PharmEasy was started in 2015, when founders Dharmil Sheth, an MBA from IMT Ghaziabad and Dr. Dhaval Shah, MBBS from Rajiv Gandhi Medical College and MBA from XLRI Jamshedpur, came up with the idea of an online pharmacy to make healthcare affordable and accessible to one and all.
Checking authentication...
Checking authentication...
PharmEasy Unlisted Shares are strategically positioned to capitalize on the rapidly expanding online pharmacy market. Driven by convenience and technological advancements, the company is set to leverage AI and innovative features to enhance customer experience and operational efficiency. Investors may find PharmEasy's growth potential in this evolving landscape particularly compelling.
PharmEasy Unlisted Shares could see increased investor interest thanks to HDFC Bank's SmartBuy portal. The program allows card members to earn significant rewards on purchases made through the site, including those from PharmEasy, potentially driving more traffic and visibility to the unlisted shares.
PharmEasy Unlisted Shares demonstrate resilience as the company navigates evolving regulatory scrutiny in the rapidly expanding e-pharmacy sector. Strategic partnerships and a focus on expanding healthcare access position PharmEasy for continued growth and investor confidence. The company's proactive approach to compliance and innovation underscores its commitment to long-term success.
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 2335 | 5729 | 6644 | 5664 |
| Cost of Material Consumed | 2267 | 5342 | 5669 | 4737 |
| Gross Margins | 2.91 | 6.76 | 14.67 | 16.37 |
| Change in Inventory | -114 | -229 | 62 | 143 |
| Employee Benefit Expenses | 270 | 1459 | 1283 | 699 |
| Other Expenses | 482 | 1502 | 1051 | 731 |
| EBITDA | -570 | -2345 | -1421 | -646 |
| OPM | -24.41 | -40.93 | -21.39 | -11.41 |
| Other Income | 25 | -1185 | -2866 | 931 |
| Finance Cost | 43 | 258 | 666 | 728 |
| D&A | 33 | 159 | 243 | 216 |
| EBIT | -603 | -2504 | -1664 | -862 |
| EBIT Margins | -25.82 | -43.71 | -25.05 | -15.22 |
| PBT | -621 | -3977 | -5196 | -2522 |
| PBT Margins | -26.6 | -69.42 | -78.21 | -44.53 |
| Tax | 21 | 22 | 15 | 11 |
| PAT | -642 | -3999 | -5211 | -2533 |
| NPM | -27.49 | -69.8 | -78.43 | -44.72 |
| EPS | -25.08 | -6.51 | -8.48 | -3.9 |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | -24.41 | -40.93 | -21.39 | -11.41 |
| Net Profit Margin | -27.49 | -69.8 | -78.43 | -44.72 |
| Earning Per Share (Diluted) | -25.08 | -6.51 | -8.48 | -3.9 |
| Shareholding Pattern | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Evermed Holdings Pte. Ltd | 14.65% | 6.45% | 6.45% | - |
| MacRitchie Investments Pte. Ltd | 13.74% | - | 11.93% | - |
| Prasid Uno Family Trust Through Its Trustee Surbhi Singh | 13.18% | 6.10% | 6.10% | 4.39% |
| TPG Growth V SF Markets Pte. Ltd | 8.73% | 7.32% | 7.32% | 7.20% |
| Lightrock Growth Fund I SA, SICAV-RAIF, For And On Behalf Of Lightrock Global Fund | 6.22% | - | - | - |
| Others | 43.48% | - | - | 57.29% |
| Naspers Ventures B. V | - | 13.24% | - | - |
| MacRitchie Investments Pte. Ltd. | - | 11.93% | - | 11.74% |
| Other | - | 54.96% | 54.96% | - |
| Naspers Ventures B. V. | - | - | 13.24% | 13.03% |
| Evermed Holdings Pte. Ltd. | - | - | - | 6.35% |
PharmEasy Unlisted Shares are strategically positioned to capitalize on the rapidly expanding online pharmacy market. Driven by convenience and technological advancements, the company is set to leverage AI and innovative features to enhance customer experience and operational efficiency. Investors may find PharmEasy's growth potential in this evolving landscape particularly compelling.
PharmEasy Unlisted Shares could see increased investor interest thanks to HDFC Bank's SmartBuy portal. The program allows card members to earn significant rewards on purchases made through the site, including those from PharmEasy, potentially driving more traffic and visibility to the unlisted shares.
PharmEasy Unlisted Shares demonstrate resilience as the company navigates evolving regulatory scrutiny in the rapidly expanding e-pharmacy sector. Strategic partnerships and a focus on expanding healthcare access position PharmEasy for continued growth and investor confidence. The company's proactive approach to compliance and innovation underscores its commitment to long-term success.
Access essential information and documents to make informed investment decisions
Stay updated with upcoming events, conferences, and announcements
Access quarterly and half-yearly financial statements and reports
Download comprehensive annual reports and financial summaries
Access investor presentations, corporate briefings, and slideshows
The current price of PharmEasy Unlisted Shares is ₹9.
The minimum lot size for investment in PharmEasy Unlisted Shares is 2500 Shares shares.
PharmEasy Unlisted Shares serves industries such as Railway Traction, Cement, Steel, Sugar, Mines, Power, Petrochemical, and Chemical Process.
The 52-week high for PharmEasy Unlisted Shares is ₹ 12, and the 52-week low is ₹ 8.5008.
The shares of PharmEasy Unlisted Shares are held in NSDL & CDSL depositories under the ISIN INE0DJ201029.
With rapid digital health adoption and expanded service offerings, consensus shows PharmEasy’s share price to move between ₹7 to ₹8 in 2025. The moderation is driven by increased market share in the online pharmacy segment, expansion into diagnostic services, an augmented product ecosystem, but due to valuation drops and profitability issues.
Read MorePharmEasy, the online pharmacy giant, is making moves to re-enter the IPO market after pulling back its initial offering two years ago. The company plans to present its revamped IPO strategy at its board meeting, which could involve a potential reverse merger with Thyrocare, its publicly listed subsidiary. This merger, along with its improved cash flow and restructured business model, is designed to boost investor confidence as PharmEasy aims to reduce its cash burn. Despite a decline in revenue by 14.7% in FY24, PharmEasy has successfully halved its net loss, primarily by cutting down on goodwill impairment charges. The company is focusing on sustainable growth while facing increased competition from rivals like Tata-owned 1mg and Apollo 24x7. PharmEasy plans to revisit its IPO strategy in 2025, with the board meeting in February 2025 serving as a key milestone for discussions.
Read MorePharmEasy is seen as a strong growth-oriented play in the digital healthcare space. Its aggressive market expansion, investment in technological infrastructure, and diversification of product and service offerings provide significant value drivers. Investors favoring growth and digital innovation are likely to find PharmEasy an attractive buy despite short-term margin pressures.
Read MoreIts risk profile is moderate-to-high, aligned with its aggressive growth trajectory. Competitive Risk: Increasing competition in the digital health and online pharmacy space. Regulatory Risk: Subject to stringent healthcare regulations and compliance standards. Execution Risk: Scaling operations quickly without sacrificing service quality.
Read MoreMr. Dharmil Sheth: Co-founder and driving force behind the company’s aggressive market expansion strategy. Mr. Vikas Bagaria: Co-founder and CEO known for his strategic focus on digital innovation and operational excellence.
Read MoreOur blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.
Discover a variety of unlisted shares beyond the popular picks. Stay updated with real-time pricing, emerging opportunities, and market trends to diversify your portfolio and make confident investment decisions.
.avif&w=256&q=75)
.avif&w=256&q=75){kind=logo}